| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085087893 |
| P356 | DOI | 10.1007/S00280-017-3324-7 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s00280-017-3324-7 |
| P698 | PubMed publication ID | 28455585 |
| P50 | author | Tateaki Naito | Q64938054 |
| Haruki Kobayashi | Q87288809 | ||
| Hirotsugu Kenmotsu | Q87952655 | ||
| P2093 | author name string | Toshiaki Takahashi | |
| Akira Ono | |||
| Takumi Fujiwara | |||
| Masahiro Endo | |||
| Kazuhisa Nakashima | |||
| Keita Mori | |||
| Haruyasu Murakami | |||
| Kazushige Wakuda | |||
| Shota Omori | |||
| Tetsuhiko Taira | |||
| Nobuaki Mamesaya | |||
| Katsuhiro Omae | |||
| Takahisa Kawamura | |||
| Mie Kotake | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics | Q27851471 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype | Q28140057 | ||
| Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer | Q33371032 | ||
| Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. | Q33384024 | ||
| Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer | Q33386055 | ||
| Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study | Q33389472 | ||
| Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy | Q34026627 | ||
| Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america | Q34160380 | ||
| Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance | Q34241858 | ||
| Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades | Q34374754 | ||
| Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer | Q34428000 | ||
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients | Q34566114 | ||
| Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications | Q34620664 | ||
| 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours | Q34625316 | ||
| The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. | Q34636362 | ||
| The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung ca | Q34727531 | ||
| Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose | Q35674153 | ||
| Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule | Q36745761 | ||
| Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice | Q40425420 | ||
| Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma | Q40545402 | ||
| A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer | Q42235917 | ||
| A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. | Q43128788 | ||
| Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer | Q43850218 | ||
| Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies | Q44119220 | ||
| Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy | Q46399690 | ||
| Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. | Q50789972 | ||
| A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. | Q52898914 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | etoposide | Q418817 |
| P304 | page(s) | 1229-1237 | |
| P577 | publication date | 2017-04-28 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum | |
| P478 | volume | 79 |
| Q93143934 | Patient factors and their impact on neutropenic events: a systematic review and meta-analysis | cites work | P2860 |
Search more.